Coherus Oncology Shares Fall on $1.75 Public Offering Price

Dow Jones02-13

By Katherine Hamilton

Coherus Oncology shares slid after the company said it would price its offering of 28 million shares at $1.75 apiece.

The stock fell 16% to $1.68 in pre-market trading Friday. Through Thursday's close, shares had gained 70% over the past 12 months.

The Redwood City, Calif., biopharmaceutical company said it expects gross proceeds from the public offering to be about $50.1 million, before deducting underwriting discounts and commissions and other expenses.

Proceeds are earmarked for support of Coherus's commercialization of its advanced nasopharyngeal carcinoma treatment Loqtorzi, as well as the clinical development of product candidates.

Underwriters have a 30-day option to buy up to an additional 4.29 million shares at the same price.

Coherus plans to close the offering on or around Feb. 17.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

February 13, 2026 06:36 ET (11:36 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2611156229?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 19:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611156229","market":"fut","top_or_hot":-1,"title":"Coherus Oncology Shares Fall on $1.75 Public Offering Price","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Coherus Oncology shares slid after the company said it would price its offering of 28 million shares at $1.75 apiece. \n</p>\n<p>\n  The stock fell 16% to $1.68 in pre-market trading Friday. Through Thursday's close, shares had gained 70% over the past 12 months. \n</p>\n<p>\n  The Redwood City, Calif., biopharmaceutical company said it expects gross proceeds from the public offering to be about $50.1 million, before deducting underwriting discounts and commissions and other expenses. \n</p>\n<p>\n  Proceeds are earmarked for support of Coherus's commercialization of its advanced nasopharyngeal carcinoma treatment Loqtorzi, as well as the clinical development of product candidates. \n</p>\n<p>\n  Underwriters have a 30-day option to buy up to an additional 4.29 million shares at the same price. \n</p>\n<p>\n  Coherus plans to close the offering on or around Feb. 17. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 13, 2026 06:36 ET (11:36 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coherus Oncology Shares Fall on $1.75 Public Offering Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoherus Oncology Shares Fall on $1.75 Public Offering Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-13 19:36</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Coherus Oncology shares slid after the company said it would price its offering of 28 million shares at $1.75 apiece. \n</p>\n<p>\n  The stock fell 16% to $1.68 in pre-market trading Friday. Through Thursday's close, shares had gained 70% over the past 12 months. \n</p>\n<p>\n  The Redwood City, Calif., biopharmaceutical company said it expects gross proceeds from the public offering to be about $50.1 million, before deducting underwriting discounts and commissions and other expenses. \n</p>\n<p>\n  Proceeds are earmarked for support of Coherus's commercialization of its advanced nasopharyngeal carcinoma treatment Loqtorzi, as well as the clinical development of product candidates. \n</p>\n<p>\n  Underwriters have a 30-day option to buy up to an additional 4.29 million shares at the same price. \n</p>\n<p>\n  Coherus plans to close the offering on or around Feb. 17. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 13, 2026 06:36 ET (11:36 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2611156229","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611156229","pubTimestamp":1770982560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Coherus Oncology shares slid after the company said it would price its offering of 28 million shares at $1.75 apiece.The stock fell 16% to $1.68 in pre-market trading Friday. Through Thursday's close, shares had gained 70% over the past 12 months.The Redwood City, Calif., biopharmaceutical company said it expects gross proceeds from the public offering to be about $50.1 million, before deducting underwriting discounts and commissions and other expenses.Proceeds are earmarked for support of Coherus's commercialization of its advanced nasopharyngeal carcinoma treatment Loqtorzi, as well as the clinical development of product candidates.Underwriters have a 30-day option to buy up to an additional 4.29 million shares at the same price.Coherus plans to close the offering on or around Feb. 17.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CHRS":"Coherus Biosciences","BK4535":"淡马锡持仓"},"translate_title":"Coherus Oncology股价因公开发行价1.75美元而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHRS":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Coherus Oncology shares slid after the company said it would price its offering of 28 million shares at $1.75 apiece. \n\n\n  The stock fell 16% to $1.68 in pre-market trading Friday. Through Thursday's close, shares had gained 70% over the past 12 months. \n\n\n  The Redwood City, Calif., biopharmaceutical company said it expects gross proceeds from the public offering to be about $50.1 million, before deducting underwriting discounts and commissions and other expenses. \n\n\n  Proceeds are earmarked for support of Coherus's commercialization of its advanced nasopharyngeal carcinoma treatment Loqtorzi, as well as the clinical development of product candidates. \n\n\n  Underwriters have a 30-day option to buy up to an additional 4.29 million shares at the same price. \n\n\n  Coherus plans to close the offering on or around Feb. 17. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 13, 2026 06:36 ET (11:36 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611156229","isCrawlerRequest":true}